Transforming Inflammatory Disease Treatment
Ayutara is a clinical-stage biopharmaceutical company developing novel, oral small-molecule therapies for chronic inflammatory diseases with significant unmet medical needs.
Advancing next-generation oral therapies for chronic inflammatory diseases with breakthrough PDE4 prodrug technology.
Ayutara is a clinical-stage biopharmaceutical company developing novel, oral small-molecule therapies for chronic inflammatory diseases with significant unmet medical needs.
Guiding principles that drive our innovation and commitment to improving healthcare
We constantly push the boundaries of what's possible in modern medicine through cutting-edge research and development.
Every decision we make begins with the patient in mind, ensuring our therapies address real-world healthcare challenges.
Our mission extends beyond borders to improve lives worldwide through accessible and effective medical solutions.
Leveraging precision chemistry to develop novel therapeutics for inflammatory diseases
Our proprietary PDE4 inhibitor prodrug platform is designed to enhance therapeutic index by improving tolerability while maintaining efficacy in treating chronic inflammatory diseases.
This approach allows for targeted delivery and reduced side effects compared to traditional PDE4 inhibitors.
We utilize advanced molecular design to create compounds that precisely target inflammatory pathways with minimal off-target effects.
Our focus on precision medicine enables us to develop treatments for specific patient populations with high unmet medical needs.
Advancing novel therapeutics for inflammatory diseases
Indication: Inflammatory Bowel Disease (IBD)
Mechanism: Oral PDE4 Inhibitor Prodrug
A novel, orally administered PDE4 inhibitor prodrug designed to improve tolerability while maintaining efficacy in treating moderate-to-severe IBD.
Indication: Atopic Dermatitis
Mechanism: Topical PDE4 Inhibitor
A topical formulation targeting inflammatory skin conditions with improved local delivery and reduced systemic exposure.
Indication: Rheumatoid Arthritis
Mechanism: Novel Anti-inflammatory Target
Early-stage program targeting a novel inflammatory pathway with potential applications in multiple autoimmune conditions.
Ayutara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel, oral small-molecule therapies for chronic inflammatory diseases with significant unmet medical needs.
Our lead program, PALI-2108, is a PDE4 inhibitor prodrug in development for inflammatory bowel disease (IBD). We leverage our proprietary prodrug platform to enhance the therapeutic index of known anti-inflammatory mechanisms, aiming to improve patient outcomes through better tolerated treatments.
Our StoryWe're seeking collaborations with pharmaceutical partners, research institutions, and investors to accelerate the development of our innovative therapies.